Skip to main content

Heroin Deaths Fell 90%. Nobody Won. Heroin Just Got Replaced.

Heroin-involved overdose deaths are down from about 15,700 a year to about 1,600, according to new CDC figures. The people who used it didn't vanish. Their drug changed underneath them, and so did the danger.

ByThe Rize NewsroomNovember 17, 20266 min readHeroin

In the summer of 2016, ethnographers working with UCSF’s Daniel Ciccarone sat down with 38 people who used heroin in northeast Massachusetts and Nashua, New Hampshire. They asked a simple question: what are you buying? The answers were unsettled in a way the researchers hadn’t heard before. The powder looked different, a different color and texture. The high came on faster and left sooner. People described buying “heroin” that they suspected wasn’t heroin at all. One woman told them that with the new product, “you get sick a lot faster, like a lot faster.” They were watching their drug change into something else, one bag at a time, years before the death certificates caught up.

Ten years later, the death certificates have caught up. New CDC provisional figures show that heroin was involved in an estimated 1,628 overdose deaths in the 12 months ending June 2026. That is down 34.8% in a single year. At the 2017 peak, the same count was 15,686. The White House drug office included the heroin drop in Monday’s release celebrating 18 straight months of falling overdose deaths.

Heroin wasn’t defeated. It was replaced, and the people who used it carried every risk forward into a harder drug.

The 90% drop is a market story, not a victory lap

Start with what the chart actually shows. Heroin deaths held flat around 15,000 a year from 2016 through 2019, and then fell off a cliff: about 13,300 in 2020, 9,300 in 2021, 6,000 in 2022, 4,100 in 2023, 2,800 in 2024. Over the same years, deaths involving synthetic opioids, mostly illicit fentanyl, climbed from under 20,000 in 2016 to more than 75,000 in 2022. Those two lines are the same story. Fentanyl is cheaper to make, easier to smuggle, and far stronger per gram. Sellers who once cut heroin with fentanyl eventually stopped bothering with the heroin. Ciccarone called this the “triple wave”: prescription pills first, then heroin, then synthetic opioids. Each wave was deadlier, and each one built on people who were already dependent on the last.

Two honest cautions about the number. First, heroin deaths have always been undercounted. Heroin breaks down into morphine within minutes of entering the body, so the telltale marker is often gone before a toxicology test runs. A 2017 Indiana University review of Marion County deaths found 455 heroin-related deaths where the official count showed 141. Second, the provisional figures are still being finalized. Neither caution changes the direction. Heroin, as a drug most Americans who use opioids can actually buy, is mostly gone.

We already know what happens when you squeeze one opioid out of a market

This has happened before, and the last time should have taught us something. In August 2010, Purdue Pharma replaced OxyContin with a reformulated version that was hard to crush, snort, or inject. It was sold as a safety measure. Economists Abby Alpert, David Powell, and Rosalie Liccardo Pacula later traced what happened next. States where more people had been misusing OxyContin saw the largest increases in heroin deaths after the reformulation. People who were dependent didn’t stop. They switched to whatever the market offered, and the market offered heroin. A decade later the market changed again and offered fentanyl. Every time the supply shifts, policymakers count the drug that’s disappearing and call it progress. The people who were using it keep using whatever is next, and each new drug has been stronger than the one before.

What the switch did to the body and the mind

The biology explains why the switch matters so much. Heroin’s high and its withdrawal followed a rhythm that long-term users knew well: a few hours of relief, then a slow, predictable slide. Fentanyl, the way it’s sold on the street, acts faster and wears off sooner. In plain terms, people chase the next dose more often, and withdrawal shows up earlier and hits harder. The Massachusetts interviewees described exactly this a decade ago, getting “sick” sooner than heroin had ever made them. Faster cycles mean more doses a day. More doses a day means more chances for one of them to be the wrong strength.

In plain terms, people chase the next dose more often, and withdrawal shows up earlier and hits harder.

The psychology changed too, and it gets talked about less. Heroin dependence was miserable, but it was predictable. You knew your dealer, your amount, your timing. Fentanyl took that away. Today’s supply is a mix that changes week to week, sometimes with a sedative or a novel opioid mixed in. Constant uncertainty is its own stress, and stress feeds cravings. If you used heroin for years and switched to fentanyl because there was nothing else, you may have noticed that you lost control faster than you ever had. That isn’t a moral failure. The drug changed. You adjusted to a supply nobody asked you about.

For treatment, the switch has practical consequences that clinicians are still working through. Starting buprenorphine after fentanyl is trickier than after heroin. Fentanyl appears to linger in fat tissue, so starting too soon can throw someone into sudden, severe withdrawal (the kind called “precipitated”). Many clinicians now use low-dose or high-dose starting methods built for this. Methadone, which works without that problem, has become more important just as federal policy is pushing grantees to talk about tapering. Naloxone still reverses fentanyl. Sometimes it takes more than one dose.

What’s still real

The national number is falling, and that matters: fewer funerals are fewer funerals. But “heroin deaths are down 90%” is a sentence about a market, not about the people who were in it. Many of them are alive, and many are in treatment. Plenty are now using a drug that’s harder to predict and harder to stop, in a system that measures its progress by what disappeared from the supply.

If you are one of them, the tools that worked on heroin still work on what replaced it. Methadone and buprenorphine both treat dependence on fentanyl. Naloxone still reverses fentanyl overdoses, and it’s sold over the counter. Ask your prescriber about a fentanyl-specific starting plan if your first try with buprenorphine went badly. A bad start doesn’t mean the medication can’t work for you. It usually means the timing was wrong. More on the class lives on our opioids hub and the heroin page, and the data desk tracks the monthly CDC release at The Crisis, By the Numbers.

The people in that 2016 study could tell their drug was changing before any federal dataset could. Ten years on, the country is finally reading the change in the death counts. The people in the study were living it the whole time.

Filed Under

trendsbiologypsychologyHeroinFentanylOverdoseGovernment DataPeer-Reviewed ResearchNaloxoneMAT — BuprenorphineMAT — Methadone

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section